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Abstract
Background: Cholangiocarcinoma (CC) is a malignant neoplasm of the bile ducts or the gallbladder. Targeting of 
growth factor receptors showed therapeutic potential in palliative settings for many solid tumors. The aim of this study 
was to determine the expression of seven growth factor receptors in CC cell lines and to assess the effect of blocking 
the EGFR receptor in vitro.
Methods: Expression of EGFR (epithelial growth factor receptor), HGFR (hepatocyte growth factor receptor) IGF1R 
(insulin-like growth factor 1 receptor), IGF2R (insulin-like growth factor 2 receptor) and VEGFR1-3 (vascular endothelial 
growth factor receptor 1-3) were examined in four human CC cell lines (EGI-1, HuH28, OZ and TFK-1). The effect of the 
anti-EGFR-antibody cetuximab on cell growth and apoptosis was studied and cell lines were examined for KRAS 
mutations.
Results: EGFR, HGFR and IGFR1 were present in all four cell lines tested. IGFR2 expression was confirmed in EGI-1 and 
TFK-1. No growth-inhibitory effect was found in EGI-1 cells after incubation with cetuximab. Cetuximab dose-
dependently inhibited growth in TFK-1. Increased apoptosis was only seen in TFK-1 cells at the highest cetuximab dose 
tested (1 mg/ml), with no dose-response-relationship at lower concentrations. In EGI-1 a heterozygous KRAS mutation 
was found in codon 12 (c.35G>A; p.G12D). HuH28, OZ and TFK-1 lacked KRAS mutation.
Conclusion: CC cell lines express a pattern of different growth receptors in vitro. Growth factor inhibitor treatment 
could be affected from the KRAS genotype in CC. The expression of EGFR itself does not allow prognoses on growth 
inhibition by cetuximab.
Background
Cholangiocarcinoma (CC) is a malignant neoplasm aris-
ing from the biliary epithelium. Most cases of CC occur
sporadically and the exact aetiology is still unknown [1].
Chronic inflammation and biliary duct cell injury
induced by the obstruction of bile flow are two of the
main conditions responsible for the development of CC
[2]. As yet complete surgical resection is the only curative
treatment for CC. Potential for resection depends on the
location and the stage of the tumor [3]. Commonly, more
than 60% of CC patients ha ve tumors not treatable by
resection [4]. Patients with an operable tumor only have a
5-year median survival rate of 9-18% for proximal biliary
lesions and 20-30% for more distal tumors [5]. Chemo-
therapy has been used in an attempt to control disease as
well as to improve survival and quality of life in patients
with irresectable, recurrent or metastatic CC [6]. Chemo-
therapy versus best supportive care (BSC) was compared
in a randomized study including both CC and pancreatic
carcinoma [7]. Patients in the chemotherapy group had
an improved quality of life compared to those in the BSC
group.
Most chemotherapies applied for CC to date are based
on 5-fluorouracil (5-FU) or gemcitabine. Median survival
times reported for palliative chemotherapy range from
4.6 to 15.4 months, which are far from desirable [6].
Radiotherapy is also insufficiently effective in treating CC
[8].
EGFR and the EGF-family of peptide growth factors
play a central role in the pathogenesis and progression of
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different carcinoma types [9,10]. Manifold actions for
other growth factors and their receptors systems have
been described in cancer, e.g. IGF (insulin-like growth
factor)/IGFR system and HGF (hepatocyte growth fac-
tor)/HGFR systems [11-13]. Based on expression data of
growth factor receptors, therapeutic targeting of these
receptors has been attempted in tumor patients.
Targeting of two of these systems, EGFR and VEGFR
has shown potential [14]. The agents which target EGFR
can be classified into two groups: tyrosine kinase inhibi-
tors (TKIs), such as gefitinib and erlotinib, and monoclo-
nal antibodies, such as cetuximab or panitumumab. In
particular, the use of cetuximab in gastrointestinal malig-
nancies has reached an advanced stage of clinical devel-
o p m e n t .  I t  h a s  b e e n  a p p r o v e d  b y  t h e  F o o d  a n d  D r u g
Administration (FDA) for the treatment of patients with
EGFR-expressing metastatic colorectal cancer. Cetux-
imab induces consistent response rates as a single agent
(approximately 10% to 15% overall response rate) and in
combination with chemotherapy in metastatic colorectal
carcinoma patients [15]. The mutation status of the
KRAS gene affects the response of cetuximab. Patients
with a colorectal tumor bearing mutated KRAS did not
benefit from cetuximab, whereas patients with a tumor
bearing wild-type KRAS did [16]. Further non-gastroin-
testinal indications for cetuximab include SCCHN
(squamous cell carcinoma of the head and neck), and
NSCLC (non-small cell lung cancer). Agents targeting
IGF/IGFR and HGF/HGFR systems are also in develop-
ment [11,17,18].
No conclusive data is available on the effect of these
new therapeutic strategies in CC. Knowledge about the
expression of growth factor receptors may guide the
development of new therapeutic strategies in CC. There-
fore, the aim of this study was to determine the expres-
sion of EGFR, IGF1R, IGF2R, HGFR and VEGFR1-3 in
four human CC cell lines. In addition, the effect of the
monoclonal anti-EGFR antibody cetuximab on cell
growth and apoptosis in two of these cell lines was stud-
ied.
Methods
Cell culture
Human CC cell lines EGI-1 and TFK-1 were purchased
from DSMZ (German Collection of Microorganisms and
Cell Cultures, Human and Animal Cell Lines, Braunsch-
weig, Germany). Human CC cell lines HuH28 and OZ
w e r e  o b t a i n e d  f r o m  H S R R B  ( J a p a n  H e a l t h  S c i e n c e s
Foundation, Health Science Research Resources Bank,
Tokyo, Japan). EGI-1 cells were cultured in Dulbecco's
MEM medium (Sigma, Munich, Germany) with 10% fetal
bovine serum (FBS), MEM essential and non-essential
amino acids (PAA, Pasching, Austria); HuH28 cells were
cultured in RPMI1640 medium with 10% FBS, MEM
essential and non-essential amino acids, sodium pyruvate
solution (PAA) and MEM vitamins (Biochrom, Berlin,
Germany), OZ cells were cultured in William's E medium
(PAN Biotech GmbH, Aidenbach, Germany) with 10%
FBS and TFK-1 cells were cultured in RPMI1640 medium
(Sigma) with 10% (FBS, PAN Biotech GmbH). EGI-1 cells
were cultured at 37°C and 10% CO2 atmosphere. HuH28,
OZ and TFK-1 cells were cultured at 37°C and 5% CO2
atmosphere.
RT-PCR
Total RNA was extracted from cells using the RNeasy
mini-Kit (Qiagen, Hilden, Germany) according to the
manufacturer's instructions. RNA was synthesised to first
strand cDNA using the Reverse Transcription System
(Promega, Madison, WI, USA) following the manufac-
turer's protocol (15 min reaction at 42°C). The reactions
were performed in a TRIO Thermoblock (Biometra,
Goettingen, Germany). To test presence and integrity of
the cDNA PCR for five different housekeeping genes was
performed (2 K Clathrin 500 bp, 6 K Clathrin 500 bp,
GAPDH 540 bp, 3'-actin 720 bp and 5'-actin 1 kb from
the Gene Checker™ Kit, Invitrogen, Leek, The Nether-
lands). The PCR comprised 25 cycles with denaturing at
94°C for 30 s, annealing at 55°C for 30 s and extension at
72°C for 30 s. PCR primers for growth factor receptors
were synthesized by TIB MOLBIOL (Berlin, Germany).
cDNA sequences were obtained from the NCBI Gen-
Bank. Primer sequences, annealing temperatures and
PCR product lengths are given in Table 1. PCR reactions
were performed with Advantage® cDNA Polymerase Mix
(Clontech, Saint-Germain-en-Laye, France). 1.2% agarose
gel (Invitrogen, Karlsruhe, Germany) was used for load-
ing of DNA products and electrophoresis. 100 bp DNA
Ladder Plus (Gene Ruler™, Fermentas, St. Leon-Rot, Ger-
many) was used as the standard. Growth factor receptor
mRNA was only determined qualitatively, no quantitative
PCR was performed.
Western blot
Cells were washed with ice-cold phosphate buffered
saline (PBS) two times, lysed in CHAPS lysis buffer
(Sigma, Munich, Germany), supplemented with DTT
(Sigma, Munich, Germany) for 30 min on ice, then soni-
cated and centrifuged for 5 min at 13.200 rpm. The
supernatant was used for Western blot. Protein samples
were separated on 4-12% Tris-Glycine gels (Invitrogen,
Novex®) with TrisGly running buffer (Novex®), transferred
onto a nitrocellulose membrane and incubated with the
following specific antibodies: polyclonal rabbit anti-
human EGFR antibody (#EGFR(1005):SC-03, Santa Cruz
Biotechnology, Santa Cruz, California, final concentra-
tion 0.5 μg/ml), mouse monoclonal anti-human HGFR
(#MAB3582, R&D Systems, Wiesbaden-Nordenstadt,Xu et al. BMC Cancer 2010, 10:302
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Germany) antibody, mouse monoclonal anti-human
IGF1R antibody (#MAB391, R&D Systems), goat anti-
human IGF2R (#AF2447, R&D Systems) antibody, mouse
monoclonal anti-human VEGFR-1 antibody (IgG1, DM
3504, Acris Antibodies, Hiddenhausen, Germany, final
concentration 1 μg/ml), mouse monoclonal anti-human
VEGFR-2 antibody (IgG1, DM 3503, Acris Antibodies,
final concentration 2 μg/ml) and mouse monoclonal anti-
human VEGFR-3 antibody (IgG, DM 3512P, Acris Anti-
bodies, final concentration 0.5 μg/ml). Horseradish per-
oxidase-conjugated antibodies were applied as secondary
antibodies: goat anti-rabbit (#SC2004, Santa Cruz Bio-
technology, final concentration 0.08 μg/ml) was used for
the detection of EGFR. Goat anti-mouse antibody
(#SC2005 Santa Cruz Biotechnology) for IGF1R and
HGFR. Donkey anti-goat antibody (#SC2020, Santa Cruz
Biotechnology) for IGF2R. Goat anti-mouse antibody
were used as secondary antibodies for the detection of
VEGFR1-3 (#A0168, Sigma, 1:5000 dilution). Immune
complexes were visualized by enhanced chemilumines-
cence (ECL Plus Kit, Amersham Biosciences, Braunsch-
weig, Germany).
Immunohistochemistry (IHC)
The following primary antibodies were used for IHC:
mouse monoclonal anti-human EGFR antibody (IgG,
#E3138, Sigma), mouse monoclonal anti-human HGFR
antibody (IgM, #MONX10170, Monosan, Am Uden, The
Netherlands), mouse monoclonal anti-human IGF1R
antibody (IgG1, #MAB391) and goat anti-human IGF2R
antibody (#AF2447 both from R&D Systems). Mouse
monoclonal anti-human VEGFR1 antibody (IgG1,
#MAB321, R&D Systems), goat polyclonal anti-human
VEGFR2 antibody (IgG, #AF357, R&D Systems) and
mouse monoclonal anti-human VEGFR-3 antibody
(IgG1, #MAB3491, R&D Systems). Mouse IgG (#M5284,
Sigma), mouse IgM (#X0942) and goat serum (#X0907,
DakoCytomation, Hamburg, Germany) were used as iso-
Table 1: Primer sequences, expected PCR product length and annealing temperature (temp) for growth factor receptor RT-PCR
Primer Product (bp) Temp (°C)
EGFR forward: 5'- ATG TCC GGG AAC ACA AAG AC -3' (2648-2667) 351 54
NM_005228.3 reverse: 5'- TTC CGT CAT ATG GCT TGG AT - 3' (2979-2998)
IGFR1 forward: 5'- ACC CGG AGT ACT TCA GCG CT -3' (2980-2999) 230 50
NM_000875.3 reverse: 5'-CAC AGA AGC TTC GTT GAG AA -3' (3190-3209)
IGFR2 forward: 5'- GCT GAC CAC TTG CTG TAG GAG AAG -3' (7162-7185) 220 50
NM_000876.2 reverse: 5'- ATC CTC ACT GTC CTG GTC ATC CC -3' (7359-7381)
HGFR forward: 5'- GGT CAA TTC AGC GAA GTC CT -3' (1481-1500) 242 50
NM_000245.2 reverse: 5'- TTC GTG ATC TTC TTC CCA GTG -3' (1702-1722)
VEGFR1 forward: 5'- TCG TGT AAG GAG TGG ACC ATC A -3' (1218-1239) 470 50
NM_002019.3 reverse: 5'- GCC AGA ACC ACT TGA TTG TAG G -3' (1690-1669)
VEGFR2 forward: 5'- GCG GTG ATT GCC ATG TTC TTC -3' (2616-2636) 550 50
NM_002253.2 reverse: 5'- CGC CGT TTC AGA TCC ACA GG -3' (3187-3168)
VEGFR3 forward: 5'- GGC AGC ATG GAG ATC GTG AT -3' (2393-2412) 380 50
NM_182925.4 reverse: 5'- GGT TGC CGA TGT GAA TGA GG -3' (2795-2776)Xu et al. BMC Cancer 2010, 10:302
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type controls. Biotinylated goat anti-mouse immunoglob-
ulins (#E0433, DakoCytomation) or biotin-SP-conjugated
mouse anti-goat-IgG antibodies (#205-065-108, Jackson
ImmunoResearch, Newmarket, England) were used as
secondary antibodies.
For IHC analysis, cells were cultured in 4-chamber
slides for 3-4 days, and fixed with 3.7% formaldehyde for
15 min. IGF1R was studied with the APAAP method.
Fixed cells were rinsed with TBS for 5 min and incubated
in TBS with 10% FBS for 60 min at room temperature.
Primary antibodies were applied in humid chambers for
60 min. The APAAP kit was used according to the manu-
facturer's instructions (DakoCytomation).
EGFR, HGFR, and IGF2R were stained by the standard
ABC procedure. After fixation and washing as described
above, 0.3% hydrogen peroxide was used to block endog-
enous peroxidase. PBS with 1% FBS was applied as block-
ing solution. Cells were incubated with primary
antibodies, biotinylated secondary anibodies and an avi-
din-biotin-peroxidase complex (Vectastain PK-6100,
Linaris, Wertheim-Bettingen, Germany). Samples were
dyed with substrate kits for peroxidase (DAB SK-4100
yielding a brown stain, VectorRed SK-4800 yielding a red
stain, both from Vector®, Linaris).
No quantification of protein expression was performed
- nor in the immunohistochemistry nor in the Western
blot experiments.
Analysis of KRAS mutations
DNA was isolated from the four human CC cell lines
EGI-1, HuH28, OZ and TFK-1 cell lines using a kit
(#51306, DNA purification Kit for genomic DNA from
tissue blood and body fluids, Qiagen) according to the
supplied protocol. Mutation analysis was done by direct
sequencing of PCR amplified KRAS exon 2 containing
codon12 and 13. PCR amplification reactions were car-
ried out in final volume of 30 μl containing 200 μM of
each dNTP, 0.3 μM of each primer, 50-100 ng genomic
template DNA, and 0.6 U Taq DNA polymerase in 1 ×
PCR buffer (Fermentas, Germany) using a MJ Research
Thermocycler (PTC100, MJ Research, Watertown, MA).
For amplification an initial denaturation step (94°C/2
min) was followed by 35 rounds of thermal cycles (94°C/1
min, 55°C/1 min, and 72°C/1 min) and a final elongation
at 72°C for 8 min.
The KRAS PCR primer sequences were 5'- TAA GGC
CTG CTG AAA ATG AC -3' (KRAS-U) and 5'- AAA
CAA GAT TTA CCT CTA TTG TTG GA -3' (KRAS-D).
PCR products were purified using the QIAquick PCR
purification kit (Qiagen) according to the supplier's pro-
tocol. DNA sequencing was performed using the ABI
Prism Big Dye Terminator Cycle Sequencing Kit 1.1
(Applied Biosystems, Weiterstadt, Germany) and an ABI
3100 AVANT capillary electrophoresis system (Applied
Biosystems) according to the manufacturer's instruction.
Cell culture for cetuximab experiments and in vitro growth 
inhibition
To evaluate the effects of cetuximab on cell growth 1 ×
104 EGI-1 and 1.5 × 104 TFK-1 cells were plated in 6-well
cell culture plates. Medium was supplemented with peni-
cillin 100 U/ml (PAA), streptomycin 0.1 mg/ml (PAA),
ciprofloxacin 0.8 mg/ml (Ciprobay® 200, Bayer Schering
Pharma AG, Leverkusen, Germany), gentamycin 50 μg/
ml (PAA) and amphotericin B 1 μg/ml (Bristol-Myers-
Squibb, Munich, Germany). Cetuximab was purchased
from Merck Pharma GmbH (Erbitux®, Darmstadt, Ger-
many). Cetuximab was diluted in medium, with final con-
centrations of 0.1 μg/ml, 1.0 μg/ml, 10 μg/ml, 100 μg/ml
and 1000 μg/ml. Time points for sub-culture of cells and
medium changes are given in figure 1. At times indicated,
cells were harvested, stained with trypan blue (Biochrom
AG, Berlin, Germany) and counted with an improved
Neubauer counting chamber (Faust, Schaffhausen, Swit-
zerland).
Flow cytometry analysis of apoptosis
Apoptosis was observed by fluorescence activated cell
sorting (FACS) analysis. At indicated time points cells
were trypsinized, washed twice with Ca2+/Mg2+ free PBS
and fixed in 70% methanol. After treatment with RNase A
(Qiagen), cells were incubated at 4°C in the dark with
propidium iodide (PI) staining solution (Sigma). After 20
minutes of incubation, apoptosis rate was determined by
flow cytometry utilizing a Coulter®  EPICS®  XL-MCL™
(Coulter, Immunotech, Krefeld, Germany) equipped with
an argon ion laser with an excitation power of 15 mW at
488 nm. The fluorescence of cells was collected on a four
decade log scale through forward light scatter (FSC) and
Figure 1 Sub-culturing of CC cell lines. Medium changes (ch) and 
time points for cell counting (count) for EGI-1 (A) and TFK-1 (B). Effects 
of cetuximab on growth of human CC cell lines was determined at the 
indicated time points. Apoptosis was observed by PI staining at the 
end of the sub-culture period.
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linear scale through right angle scatter (SSC). Fluores-
cence for PI was collected at 620 nm (FL3). Analysis gates
were set around debris and intact single cells on a PI ver-
sus AUX dot plot. Data were analyzed by the ExpoTM32
ADC program (Beckman Coulter, Krefeld, Germany).
Statistics
All experiments were performed in triplicate. Data are
expressed as mean ± s.d. Statistical analysis was per-
formed using the Student's t test. Differences were con-
sidered significant with a P  value of < 0.05. Curve
progression of cell growth in cetuximab experiments was
calculated with SPSS version 13·0.1 (Apache Software
Foundation, Forest Hill, MD, USA). Differences were
considered significant at a PGLM-value of < 0.001.
Results
mRNA expression of growth factor receptors in human CC 
cell lines
The four CC cell lines were cultured as described. RNA
was isolated and the integrity of mRNA was verified by
RT-PCR with the Gene Checker™ kit proving presence
and integrity (figure 2A). Negative control reactions were
performed without cDNA. Growth factor receptor
mRNA was analyzed in the CC cell lines. EGFR, HGFR,
IGF1R, IGF2R and VEGFR1 were detected in all four cell
lines (figure 2B). VEGFR2 was found in EGI-1, HuH28
and OZ but not in TFK-1. VEGFR3 RT-PCR was success-
ful with cDNA from EGI-1, OZ and TFK-1 but not with
cDNA from HuH28.
Protein expression of growth factor receptor in human CC 
cell lines
To investigate whether mRNA expression was followed
by translation into protein we performed Western blots
with lysates from EGI-1, HuH28, OZ and TFK-1. The 170
kDa EGFR protein was detectable in all four human CC
cell lines (figure 3). The heterodimeric mature form of the
190 kDa HGFR protein is processed to a 145 kDa and 50
kDa subunit. In EGI-1, HuH28 and TFK-1 the 145 kDa β
chain was detected. The 50 kDa α chain was present in all
four cell cultures. Hence, HGFR was considered to be
expressed in all studied CC cell lines. Two bands of the
heterotetrameric transmembrane protein IGF1R protein
were found in EGI-1 and TFK-1 representing the two
alpha-subunits of 135 kDa and two beta-subunits of 95
kDa (figure 3). IGF2R protein (300 kDa) was found in all
of the four cell lines with strong immunoreactive bands.
No evidence was seen for VEGFR1 protein (180 kDa)
expression. The 200 kDa VEGFR2 band was clearly
detectable in EGI-1 and OZ. A weak signal was obtained
for HuH28. VEGFR3 protein (195 kDa) was determined
in EGI-1, HuH28 and OZ. A faint signal could be identi-
fied in TFK-1.
Figure 2 RT-PCR for housekeeping genes and growth factor re-
ceptors. A) PCR analysis to ensue the presence and integrity of five 
housekeeping genes from TFK-1, representative for all cell lines used. 
B) mRNA expression of growth factor receptors in four CC cell lines (n. 
d. = not detected).
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Figure 3 Western blot for growth factor receptors from different 
CC cell lines. EGFR, HGFR, IGF2R, VEGFR2 and 3 was detected in EGI-1, 
HuH28, OZ and TFK-1. IGF1R was visualized in EGI-1 and TFK-1. VEGFR1 
was not in the investigated cell lines (n. d. = not determined).Xu et al. BMC Cancer 2010, 10:302
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Growth factor receptor immunohistochemistry
As mRNA and protein expression of the investigated
growth factor receptors were confined to EGI-1, HuH28,
OZ and TFK-1 by RT-PCR and Western blot, we con-
firmed protein expression in CC cell lines by IHC. Cells
were grown on glass slides and analyzed at different states
of confluence. Anti-EGFR antibody and the correspond-
ing secondary antibody was applied and visualized by the
standard ABC procedure. DAB substrate dye resulted in a
brown reaction product. Immunostaining for EGFR dem-
onstrated a clear protein expression in EGI-1 and TFK-1
(figure 4A and 4C). No detectable staining was obtained
when a mouse IgG1 isotype was used as negative control
(figure 4B and 4D). Staining of HuH28 and OZ yielded a
diffuse brown color (figure 4E and 4G) as compared to
isotype control (figure 4F and 4H).
Anti-HGFR, -IGF2R, -VEGFR1 and 2 were applied with
secondary antibodies. An intensive brown staining was
demonstrated using ABC and DAB for the growth factor
receptors as shown for HuH28 representative for all four
cell lines (figure 4I, K, L, M). No detectable staining was
obtained when isotype control antibodies were used as
negative control (not shown). IGF1R and VEGFR3 were
visualized by the APAAP procedure and dyed with Vec-
torRed substrate resulting in a clear red reaction product
(figure 4J and 4N) compared to isotype control (not
shown).
Effects of cetuximab on growth of human CC cell lines
EGFR mRNA expression was determined by RT-PCR in
EGI-1, HuH28, OZ and TFK-1 and further confirmed by
Western blot and IHC. As Ras activation is likely to pro-
mote tumor cell proliferation to assess whether successful
inhibition of the EGFR signaling pathway is associated
with KRAS mutations cell lines were examined for KRAS
gene mutations. To confirm mutated KRAS alleles, we
extracted the corresponding genomic DNA and
sequenced the KRAS  locus. In EGI-1 a heterozygous
mutation was found in codon 12 (c.35G>A; p.G12D).
Codon 12 mutations usually lead to KRAS activation in
colorectal cancer cell lines, but the activation status was
not formally tested in EGI-1 [19]. HuH28, OZ and TFK-1
were confirmed to display the wild-type allele. This evi-
dence suggests that in HuH28, OZ and TFK-1 no consti-
tutive activation of the KRAS gene is present (data not
shown). Two cell lines carrying either wild-type or
mutated KRAS were chosen to test the effect of cetux-
imab on cell growth and apoptosis. We selected EGI-1
and TFK-1 for treatment with increasing concentrations
of cetuximab (final concentrations 0.1-1000 μg/ml). The
fast-growing cells were plated in 6-wells, supplied with
sufficient media and sub-cultured to avoid confluence
(figure 1A). Cells were counted with an improved Neu-
bauer chamber at day 4, 7 and 10 (figure 5A) and day 11,
14 and 17 of sub-culture (not shown). Within 10 days
non-stimulated EGI-1 proliferated from 1 × 104 to 1.7 ×
105 cells. Under stimulation with cetuximab they grew to
1.5 × 105-0.9 × 105 cells. Cetuximab showed no dose-
d e p e n d e n t  e f f e c t  o n  c e l l  g r o w t h  i n  E G I - 1 .  N o  g r o w t h
inhibition was observed between initially seeded and sub-
cultured EGI-1.
TFK-1 were counted at day 4, 7, 10 and 14 (figure 5B)
and day 14, 17, 20 and 24 of sub-culture (not shown).
Within 14 days non-stimulated TFK-1 proliferated from
1.5 × 104 to 2.3 × 105 cells. In contrast to EGI-1, TFK-1
displayed a dose-dependent inhibition of cell growth
exerted by cetuximab. Stimulation with the anti-EGFR
antibody decreased growth to 1.4 × 105 cells with 0.1 μg/
ml cetuximab up to 0.3 × 105 cells with 1000 μg/ml. The
same result was found in the sub-cultured cells.
Effects of cetuximab on apoptosis of human CC cell lines
Stimulation with cetuximab showed no dose-dependent
effect on cell growth in EGI-1 but a significant inhibition
of cell growth in TFK-1 in both the initially seeded and
sub-cultured cells. To assess whether cetuximab stimula-
tion results in apoptotic effects fragmented DNA was
measured by flow cytometry after PI staining. The per-
centages of apoptotic cells are depicted by the sub-G1
Figure 4 IHC for growth factor receptors on different CC cell lines. 
Immunostaining of EGFR on EGI-1 (A), HuH28 (C), OZ (E) and TFK-1 (G) 
with the according isotype staining (B, D, F and H). Immunostaining of 
HGFR (I), IGF1R (J), IGF2R (K), VEGFR1 (L), VEGFR2 (M) and VEGFR3 (N). 
IHC revealed expression of the growth factor receptors tested in all hu-
man CC cell lines. ABC procedure (A-I, K-M) and APAAP method (J and 
N). Original magnification × 200.
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peak (M1) of fragmented DNA in figure 6. Treatment of
cultured EGI-1 with cetuximab did not increase the num-
ber of apoptotic cells (not shown). An increase of apopto-
sis of from 4.5% to 7.6% in the initially seeded cells and
from 7.2% to 17.6% in the sub-cultured TFK-1 was
observed at the highest cetuximab concentration (1000
μg/ml). These data indicate that cetuximab mediates
apoptotic effects in TFK-1 cells at high doses.
Discussion
In  r ec e n t yea r s,  t he  r ol e  of  EG FR  in CC  has bee n t he
focus of several studies. EGFR expression was examined
in 20 surgically resected liver tissues with CC by IHC and
25% (5/20) were EGFR-positive suggesting that this
g r o w t h  h o r m o n e  r e c e p t o r  i s  a s s o c i a t e d  w i t h  C C  [ 2 0 ] .
Nonomura et al. found EGFR in 32% of cases with intra-
hepatic CC by immunocytochemistry and reported some
cases of co-expression with EGF, suggesting autocrine
growth stimulation [21]. Another group analyzed the role
of EGFR in intrahepatic CC [22]. EGFR expression was
found to be correlated with frequency of lymph node
metastases, aberrant p53 expression, proliferative activity
and differentiation of the carcinoma. In a recent publica-
tion on EGFR expression in 236 cases of CC EGFR
expression was a significant prognostic factor and also a
risk factor for tumour recurrence in intrahepatic CC [23].
These results confirm that EGFR expression is associated
with tumour progression.
EGFR has been attributed an important role in carcino-
genesis of several tumor types and EGFR inhibitors are
currently used in treatment of some of them [24-28].
Yoon et al. reported that EGF stimulation increased cell
growth in CC cells [29]. The effect was significantly
diminished by EGFR kinase inhibitors. A growth inhibi-
tory effect of cetuximab has demonstrated in several cell
lines of non-CC origin, e.g. in squamous cell [30], colon
[31], head and neck [32], non-small cell lung [28], pros-
tate [33], renal carcinoma [27] and glioblastoma [34]. It
has been reported that the monoclonal anti-EGFR-anti-
body cetuximab was active against various tumors
including colorectal [24], head and neck [25], non-small
cell lung [28], prostate [26] and renal cancer [27]in vivo.
Sprinzl et. al. described the treatment of a patient with a
non-resectable CC in a case report [35]. Combination of
cytotoxic chemotherapy together with cetuximab showed
Figure 6 Effects of cetuximab on apoptosis of TFK-1 cells. Single 
cell gate (A) and PI staining after 24 days of culture (B-G). Cetuximab 
mediates apoptotic effects in TFK-1 cells at 1000 μg/ml only.
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promising efficacy. Blocking EGFR on CC cells could rep-
resent a therapeutic approach in respect to survival and
quality of life [35]. A recent publication assessed the effi-
cacy of cetuximab in the palliative treatment of patients
with intrahepatic CC unresponsive to first-line gemcit-
abine-oxaliplatin pretreatment. In tumor cells EGFR
expression was found by IHC in 7 from 9 patients without
gene amplification [36]. Therapy with both cetuximab
and gemcitabine-oxaliplatin was suggested as palliative
treatment in patients with advanced intrahepatic CC.
So far, there are no reports on the effects of cetuximab
on growth inhibition in CC cell lines. The human CC cell
lines used have been developed from different histologi-
cal types and different stages of CC. EGI-1 was estab-
lished from a bile duct carcinoma with advanced stage
malignancy [37]. The initial tumor presented with seeded
metastases and was histologically characterized as a large
cell adenocarcinoma of low differentiation. HuH28 was
established from liver bile duct carcinoma. OZ was estab-
lished from ascitic effusion of a patient who suffered from
obstructive jaundice due to the clogging of the common
bile duct with mucinous substances produced by adeno-
carcinoma cells [38]. TFK-1 was grown from a surgically
resected tumor (extrahepatic bile duct carcinoma) speci-
men, which had parts of a papillary adenocarcinoma and
a differentiated tubular adenocarcinoma on histology
[39]. EGFR expression was confirmed on all four CC cell
lines by RT-PCR, Western blot and IHC. For EGFR this is
consistent with data on other human CC cell lines:
HuCCT1 express EGFR mRNA [40] and KMBC contain
EGFR protein [41]. As inappropriate Ras activation is
known to promote tumor cell proliferation we examined
the four cell lines for KRAS gene mutations. In EGI-1 a
heterozygous mutation was found. HuH28, OZ and TFK-
1 were confirmed to display the wild-type allele. Consti-
tutively activated Ras is associated with continuous
growth stimulation. The cell lines EGI-1 and TFK-1 were
chosen for growth inhibition experiments to further
compare the two different KRAS genotypes. Cetuximab
did not significantly inhibit cell growth in EGI-1 cells, but
had a dose-dependent effect on growth of TFK-1 cells.
This evidence suggests that the outcome of growth factor
inhibitor treatment could be affected from the K-ras gen-
otype.
Y oon et al found that EGFR activation was sustained
following EGF stimulation in cholangiocarcinoma cells as
compared to hepatoma cells [29]. They used KMBC and
Witt cell lines. EGFR activation resulted in p42/44 MAPK
activation. Cell growth was increased in cholangiocarci-
noma following EGF stimulation and this was signifi-
cantly attenuated by kinase inhibitors. To our knowledge,
as yet, no study has compared the growth inhibitory
effects of EGFR antibodies and kinase inhibitors. This
group further found a defective receptor internalization
in a CC cell line. However, they did not look into KRAS
mutations. It would be of interest to study cells used by
Yoon et al. with respect to their KRAS status.
As it was reported that cetuximab can induce apoptosis
in tumor cells in vitro and in vivo [26,42,43], we tested the
e f f e c t  o f  c e t u x i m a b  o n  c e l l  s u rv i v a l .  A s  w e  w a n t e d  t o
compare cell lines with activating KRAS mutation and
without with respect to their response to cetuximab the
cell lines EGI-1 (with activating KRAS mutations) and
TFK-1 (without KRAS mutations) were chosen for
growth inhibition experiments to further compare the
two different KRAS genotypes. Cetuximab did not signif-
icantly inhibit cell growth in EGI-1 cells (containing the
activating KRAS mutation), but had a dose-dependent
effect on growth of TFK -1 cells. This suggests that the
outcome of cetuximab treatment of CCC cell lines could
be affected by the K-ras genotype. Therefore other modes
of action might be involved in the effects observed on the
growth of TFK-1 at least at lower cetuximab concentra-
tions. The amount of EGFR present on the cell surface
was not measured in our experiments. In colorectal can-
cer, there is no direct correlation between the amount of
EGFR on the cell surface and the effects of EGFR block-
ade  in vivo. And EGFR-negative colorectal cancer
patients have been reported to respond to cetuximab
treatment. From our data, it could be speculated that
similar effects might be seen in CC. Further research is
needed to demonstrate whether histology can predict a
response to EGFR blockade in CC. Growth inhibition of
cetuximab in TFK-1 cells was dose-dependent. This may
imply that higher concentrations in vivo have more pro-
nounced therapeutic effects. In contrast to cholangiocar-
cinoma in colorectal cancer, dose-escalating studies are
on its way and their results are awaited.
M o r e  l i m i t a t i o n s  a p p l y  t o  o u r  s t u d y:  w e  s t u d i ed  c e l l
lines and it is inherent that the results may not be readily
transferable to the in vivo situation. Moreover, although
we used four different cell lines for the mRNA and pro-
tein expression experiments and two for the studies on
the effect of cetuximab, these numbers are still low com-
pared to the myriad of differences which should be found
in different tumors in vivo. Nevertheless, the results of
this study help to generate relevant questions for research
in the treatment of cholangiocarcinoma. One of them is
that KRAS mutations should be examined in the clinical
trials on the effect of EGFR blockade in this tumor type.
In our experiments HGFR was detected in all four CC
cell lines by RT-PCR, Western Blot and IHC. Others
found HGFR mRNA in rat cell line CC-62, which was
derived from a combined hepatocellular and cholangio-
cellular carcinoma [44]. HGFR expression is high in well-
differentiated tumors and relatively low in poorly differ-
entiated tumors [45]. Antagonizing the binding of HGF
to HGFR also inhibited invasion in HuCC-T1, a humanXu et al. BMC Cancer 2010, 10:302
http://www.biomedcentral.com/1471-2407/10/302
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C C  c e l l  l i n e ,  i n  v i t r o  a n d  i n  v i v o  [ 4 6 ]  s u g g e s t i n g  t h a t
blockade of HGFR might be a therapeutic strategy which
should be the focus of further studies.
IGF1R expression was confirmed in the four CC cell
lines tested by RT-PCR and IHC. Western blot showed
protein expression in EGI-1 and TFK-1. Alvaro et. al.
r e p o r t e d  t h a t  I G F 1 R  i s  e x p r e s s e d  i n  t h e  C C  c e l l  l i n e s
HuH-28, TFK-1 and Mz-ChA-1 [47] which supports our
finding. IGF1R antagonists can inhibit proliferation of
CC cell lines after serum deprivation and re-administra-
tion. In addition, IGF1R antisense oligonucleotides
diminished cell growth in HuH-28 cells [47]. Increased
expression of IGF1R promotes ligand-dependent malig-
nant transformation in various cell systems [48]. To our
knowledge, there have been no reports on the expression
o n  I G F 2 R  i n  C C  c e l l  l i n e s  o r  C C.  I n  o u r  e x pe r i m e n t s
IGF2R mRNA and protein expression was found in EGI-
1, HuH28, OZ and TFK-1 with all methods applied.
VEGFR1 expression was found by RT-PCR and IHC in
the four CC cell lines tested but not with Western blot. To
date, there is poor knowledge about the expression of
VEGFR in CC. Benckert et. al. confirmed VEGFR1 in 15
of 19 tumor samples in human CC biopsies by IHC and in
in situ hybridization [49]. It was suggested that a malig-
nant phenotype is associated with increased VEGFR1
expression.
This study has several limitations. First, only CC cell
lines were used. These cells lines may have gained addi-
tional mutations during the many passages under in vitro
conditions. This may be a reason for the detection of
VEGFR3 mRNA in the absence of detectable protein.
F u r t h e r ,  w e  o n l y  i n v e s t i g a t e d  t h e  b l o c k a d e  o f  E G F R .
Other growth factor receptors may be crucial for the
growth of CC cells. In addition we regarded TFK-1 cells
as an example of CCC cell lines with WT KRAS and did
not study HuH28 and OZ cells. This all limits the impact
of this study.
Conclusion
The CC cell lines investigated in this study express EGFR,
HGFR and IGF2R. Some also display IGF1R and
VEGFR1-3. Cetuximab did not significantly inhibit cell
growth in EGI-1 cells carrying a heterozygous KRAS
mutation, but had a dose-dependent effect on growth of
TFK-1 cells displaying the KRAS wild-type. Thus growth
factor inhibitor treatment could be affected from the
KRAS genotype in CC similarly to data in colorectal car-
c i n o m a.  T h e  e x p r e s s i o n  o f  E G F R  i ts e l f  d o e s  n o t  a l l o w
prognoses on growth inhibition by cetuximab.
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